Clinical Trial Update: Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating a bispecific CD19/CD22 CAR-T therapy for children and young adults with refractory/relapsed B-ALL, across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• unspecified bispecific CD19/CD22 CAR-T therapy (CD19/CD22 bispecific CAR-T)

Snippet

Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Conditions: B-ALL | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING